Respiratory

Pulmonary embolism in pregnancy: diagnosis and treatment

Clinical Overview and When to Suspect PE in Pregnancy

— Hypercoagulability: rising estrogen increases factors V, VIII, X, fibrinogen, and von Willebrand factor; protein S decreases; acquired activated protein C resistance develops

— Venous stasis: gravid uterus compresses IVC and left iliac vein (left-leg DVT predominance)

— Endothelial injury: at delivery, especially cesarean

— New or worsening dyspnea (must distinguish from physiologic dyspnea of pregnancy)

— Pleuritic chest pain, tachycardia out of proportion, hemoptysis, syncope

— Unilateral leg swelling/pain (especially left)

— Unexplained hypoxemia, sinus tachycardia >100, or RV strain on imaging/ECG

— Prior VTE (single strongest), known thrombophilia (factor V Leiden, prothrombin G20210A, antiphospholipid syndrome)

— Cesarean delivery (especially emergent), obesity (BMI ≥30), age >35, multiparity, multiple gestation

— Preeclampsia, immobilization, hyperemesis with dehydration, ART/IVF, postpartum hemorrhage, infection/sepsis

— Smoking, sickle cell disease, SLE, IBD

Board pearl: A pregnant or postpartum patient with unexplained tachycardia, dyspnea, or hypoxemia must have PE actively excluded — do not anchor on "anxiety" or "deconditioning." Maternal mortality from PE is largely a failure-to-diagnose problem; the workup threshold should be lower, not higher, than in nonpregnant patients, and imaging radiation concerns should not delay diagnosis.

Pulmonary embolism (PE) is a leading cause of maternal mortality in high-income countries, accounting for ~9% of pregnancy-related deaths in the US.

Pregnancy is a hypercoagulable state — Virchow's triad is fully activated:

Risk is elevated throughout pregnancy but peaks postpartum — relative risk ~5x antepartum, ~20–80x in the first 6 weeks postpartum, returning to baseline by ~12 weeks.

When to suspect:

Major risk factors:

Presentation Patterns and Key History

— Dyspnea (~80%) — but ~70% of normal pregnancies report some dyspnea

— Pleuritic chest pain (~50%) — more specific

— Cough (~20%), hemoptysis (rare but high-yield)

— Syncope or presyncope — concerning for hemodynamically significant PE

— Unilateral calf/thigh swelling, pain, warmth — DVT often precedes PE

— Sudden onset rather than gradual progression over trimesters

— Resting dyspnea or orthopnea/PND

— Associated pleuritic pain or hemoptysis

— Persistent tachycardia >100 or hypoxemia (SpO₂ <95%)

— Unilateral leg findings

— Personal/family VTE history, known thrombophilia

— Recent immobility, long-distance travel, hospitalization, surgery

— Mode of delivery (cesarean ↑↑ risk), postpartum interval, hemorrhage requiring transfusion

— Current anticoagulation or recent missed doses

— Prior preeclampsia, recurrent miscarriage (suggests antiphospholipid syndrome)

— Infection, dehydration, hyperemesis

— Smoking, BMI, age, parity, multiple gestation, ART use

Key distinction: Physiologic dyspnea of pregnancy is gradual, present at rest but not worsened by exertion, unaccompanied by tachycardia or hypoxemia, and develops over weeks — typically starting in the second trimester due to progesterone-driven hyperventilation. PE dyspnea is abrupt, associated with tachycardia, often pleuritic, and not improved by rest. Any pregnant patient with sustained HR >100, RR >20, or SpO₂ <95% on room air warrants objective PE evaluation regardless of how "anxious" she appears.

Board pearl: Postpartum patients presenting to the ED 1–6 weeks after delivery with "panic attacks" or vague chest discomfort are a classic PE miss — always check vitals trend and SpO₂.

Classic symptoms mirror nonpregnant patients but overlap heavily with normal pregnancy physiology:

Red-flag features distinguishing PE from physiologic pregnancy dyspnea:

Key history to elicit:

Physical Exam Findings and Hemodynamic Assessment

— Tachycardia (HR >100) — most consistent finding, but baseline pregnancy HR is already ~10–15 bpm higher

— Tachypnea (RR >20)

— Hypoxemia — SpO₂ <95% on room air is abnormal in pregnancy; check A-a gradient (widened with PE)

— Hypotension (SBP <90 or drop >40 from baseline) — defines massive/high-risk PE

— Low-grade fever possible

— Often normal or shows focal crackles, decreased breath sounds, pleural rub

— Wheezing is uncommon — should prompt asthma/anaphylaxis consideration

— Loud P2, fixed split S2, RV heave, S3 or S4 gallop

— JVD elevation (interpret carefully — pregnancy alters baseline)

— Tricuspid regurgitation murmur

— Unilateral edema, calf tenderness, Homan sign (insensitive), palpable cord — especially left leg due to left iliac compression by gravid uterus and right iliac artery (May-Thurner physiology accentuated)

— Massive (high-risk): sustained hypotension, shock, cardiac arrest

— Submassive (intermediate-risk): normotensive but RV dysfunction on echo/CT or elevated troponin/BNP

— Low-risk: normotensive, no RV strain, normal biomarkers

Step 3 management: A pregnant patient with suspected PE plus hypotension needs immediate bedside echocardiogram — if RV strain is present and patient is unstable, empiric anticoagulation and consideration of systemic thrombolysis should not be delayed by definitive imaging. Pregnancy is not an absolute contraindication to thrombolytics when the alternative is maternal death; tPA does not cross the placenta in clinically significant amounts.

Vital signs are the most sensitive bedside screen:

Pulmonary exam:

Cardiac exam — signs of RV strain (concerning for submassive/massive PE):

Lower extremity:

Hemodynamic categorization (parallels nonpregnant ESC/AHA):

Diagnostic Workup — Initial Labs, ECG, and CXR

— Hypoxemia or widened A-a gradient supports PE

— Normal pregnancy: mild respiratory alkalosis (PaCO₂ 28–32), compensated; PaO₂ should be >100

— Most common: sinus tachycardia

— Classic but uncommon: S1Q3T3, right axis deviation, RBBB, T-wave inversions in V1–V4 (RV strain pattern)

— Rules out STEMI as alternate explanation for chest pain

— Often normal; may show Westermark sign (oligemia), Hampton hump (wedge infarct), atelectasis, small effusion

— Critical for excluding pneumonia, pneumothorax, pulmonary edema

— Shielded abdominal CXR delivers <0.1 mGy to fetus — well below teratogenic threshold (~50 mGy). Do not defer.

— Physiologically elevated in pregnancy — rises each trimester, peaks postpartum

— Standard cutoffs (500 ng/mL) have poor specificity but negative D-dimer with low clinical pretest probability still has reasonable NPV

— Pregnancy-adjusted cutoffs (e.g., YEARS algorithm adapted for pregnancy or trimester-specific thresholds) are increasingly used to safely avoid imaging

— A normal D-dimer in a low-risk pregnant patient using the pregnancy-adapted YEARS protocol can rule out PE without imaging

— Troponin, BNP/NT-proBNP — elevated values suggest RV strain (submassive PE)

— CBC, BMP, coagulation panel as baseline before anticoagulation

— Type and screen if delivery anticipated or hemorrhage risk

Board pearl: Do not skip D-dimer in pregnancy — the pregnancy-adapted YEARS algorithm (clinical signs of DVT, hemoptysis, PE most likely dx; D-dimer <1000 if 0 items or <500 if ≥1 item) safely excludes PE in ~40% of pregnant patients without any radiation exposure to mother or fetus.

Start with bedside and basic studies to risk-stratify and exclude mimics:

Pulse oximetry and ABG:

ECG (obtain in all suspected PE):

Chest X-ray:

D-dimer:

Other labs:

Diagnostic Workup — Advanced and Confirmatory Imaging

— Step 1: Bilateral lower extremity compression ultrasound if leg symptoms present — if positive DVT, treat as PE without further imaging (no radiation)

— Step 2: Chest imaging — choice between CT pulmonary angiography (CTPA) and V/Q scan depends on local availability and CXR findings

— Higher maternal breast radiation (~10–70 mGy to breast tissue) — slight ↑ lifetime breast cancer risk

— Lower fetal dose (~0.01–0.66 mGy) than V/Q

— Preferred if CXR abnormal, or if alternate diagnosis (dissection, pneumonia) is being considered

— Provides anatomic detail and RV/LV ratio for severity

— Slightly higher fetal dose (~0.1–0.8 mGy) but much lower maternal breast dose

— Preferred if CXR is normal and patient is young with no underlying lung disease

— High negative predictive value when normal

— Not diagnostic for PE but identifies RV strain, McConnell sign, septal flattening, elevated PASP, RV thrombus

— Essential for unstable patients to guide thrombolysis decisions

Key distinction: Normal CXR → V/Q scan preferred (lower breast dose, accurate). Abnormal CXR or alternative dx considered → CTPA. Either is acceptable; failure to image is the dangerous choice.

If pretest probability is intermediate/high or D-dimer/YEARS is positive, proceed to imaging — do NOT delay due to radiation fears.

Algorithm in pregnancy:

CT pulmonary angiography (CTPA):

V/Q scan (perfusion-only often used in pregnancy):

Both modalities deliver fetal radiation well below the 50 mGy teratogenic threshold — counsel reassurance.

MRI/MR pulmonary angiography: limited role; gadolinium avoided in pregnancy (crosses placenta).

Echocardiography:

Contraindication caveats: Iodinated contrast (CTPA) crosses placenta — transient neonatal hypothyroidism risk is theoretical; check newborn TSH but do not withhold CTPA.

Risk Stratification and Management Logic

— Sustained hypotension (SBP <90 for >15 min), shock, vasopressor requirement, or cardiac arrest

— Mortality ~25–50% in pregnancy

— Requires immediate reperfusion (thrombolysis, catheter-directed therapy, or surgical embolectomy) + anticoagulation

— ICU admission, multidisciplinary "PERT" (Pulmonary Embolism Response Team) activation

— Normotensive but evidence of RV dysfunction (echo/CT RV/LV >0.9, elevated BNP) and/or myocardial necrosis (troponin+)

— Anticoagulation + close monitoring; thrombolysis case-by-case if deterioration

— Step-down or ICU admission

— Normotensive, no RV strain, normal biomarkers

— Therapeutic LMWH and admission for monitoring; outpatient management is generally not offered to pregnant patients given delivery planning needs and adherence stakes

— Gestational age (delivery planning, neuraxial anesthesia timing)

— Distance to delivery (anticoagulation switch window)

— Bleeding risk: placental abruption, placenta previa, recent surgery, postpartum hemorrhage history

— Renal function (LMWH dosing)

Step 3 management: For a hemodynamically stable pregnant patient with confirmed PE, the immediate orders are: (1) admit to monitored bed, (2) therapeutic LMWH (enoxaparin 1 mg/kg SC q12h based on early-pregnancy weight), (3) baseline CBC, creatinine, LFTs, type & screen, (4) maternal-fetal medicine and hematology consults, (5) fetal monitoring appropriate for gestational age, (6) DVT prophylaxis with mechanical compression devices contralateral leg, (7) counsel on signs of bleeding and recurrent PE.

CCS pearl: Advance the clock 24 hours; check anti-Xa level if dosing uncertainty exists, recheck CBC, plan delivery strategy.

Once PE is confirmed, stratify by hemodynamic severity — this drives therapy intensity:

Massive (high-risk) PE:

Submassive (intermediate-risk) PE:

Low-risk PE:

Pregnancy-specific considerations layered on top:

PESI/sPESI scores were not validated in pregnancy — use clinical judgment.

Pharmacotherapy — First-Line Anticoagulation

— Enoxaparin 1 mg/kg SC q12h (therapeutic) — preferred over daily dosing in pregnancy due to altered PK

— Alternative: dalteparin 100 units/kg SC q12h or 200 units/kg daily

— Use early-pregnancy (or pre-pregnancy) weight for dosing; adjust if significant weight change

— Anti-Xa monitoring (peak, 4 h post-dose, target 0.6–1.0 IU/mL) — recommended in extremes of body weight, renal impairment, recurrent VTE, or near delivery

— Used when rapid reversibility needed (impending delivery, high bleeding risk, severe renal failure CrCl <30)

— Continuous IV infusion, titrate to aPTT 1.5–2.5x or anti-Xa 0.3–0.7

— Also does not cross placenta

— Warfarin — crosses placenta, teratogenic (warfarin embryopathy: nasal hypoplasia, stippled epiphyses) at 6–12 weeks; fetal bleeding/CNS abnormalities later; acceptable postpartum and compatible with breastfeeding

— DOACs (apixaban, rivaroxaban, dabigatran, edoxaban) — cross placenta, insufficient safety data, contraindicated in pregnancy and breastfeeding

— Fondaparinux — limited data; reserve for HIT or LMWH allergy

— Therapeutic anticoagulation throughout remainder of pregnancy AND at least 6 weeks postpartum, total minimum 3 months

— Switch to UFH or hold LMWH 24 h before planned delivery/neuraxial anesthesia

— Restart 12–24 h postpartum depending on bleeding risk

— Neuraxial anesthesia contraindicated within 24 h of therapeutic LMWH (12 h prophylactic)

Board pearl: LMWH = pregnancy. Warfarin = postpartum (safe with breastfeeding). DOACs = never in pregnancy or lactation. Memorize this triad.

Low-molecular-weight heparin (LMWH) is the first-line agent in pregnancy — does not cross the placenta, no teratogenicity, predictable pharmacokinetics.

Unfractionated heparin (UFH):

Avoid in pregnancy:

Duration:

Peripartum management:

Advanced and Invasive Therapies for Massive PE

— Hemodynamic instability (massive PE), cardiac arrest, refractory hypoxemia, or rapid deterioration despite anticoagulation

— tPA (alteplase) 100 mg IV over 2 hours (or 0.6 mg/kg bolus in arrest)

— Pregnancy is a relative, not absolute, contraindication — does not cross placenta in clinically meaningful amounts

— Major risk: maternal hemorrhage ~8%, fetal loss ~6%, preterm delivery ~6%

— Use when maternal survival is at stake — risk of withholding > risk of giving

— Avoid in immediate peripartum period (24 h pre/post delivery) due to catastrophic hemorrhage risk

— Catheter-directed thrombolysis (lower-dose tPA via pulmonary artery catheter) or mechanical/aspiration thrombectomy (e.g., FlowTriever, Inari)

— Lower systemic bleeding risk — increasingly preferred in pregnancy when available

— Requires PERT and interventional radiology/cardiology

— Reserved for failed thrombolysis, contraindications to lytics (active hemorrhage, recent surgery, immediate peripartum), or right heart thrombus

— Requires cardiopulmonary bypass — anticoagulation/heparinization can be managed; fetal monitoring intraoperatively when viable

— Indicated when anticoagulation is absolutely contraindicated (active bleeding) or recurrent PE despite therapeutic anticoagulation

— Retrievable filter preferred, placed suprarenally in pregnancy to avoid compression by gravid uterus

— Remove postpartum once anticoagulation safely resumed

Step 3 management: Pregnant patient in shock with confirmed massive PE → activate PERT, bedside echo, alteplase 100 mg over 2 h unless active bleeding or imminent delivery, in which case mechanical thrombectomy or surgical embolectomy preferred. Do not let "she's pregnant" cause therapeutic nihilism — maternal death kills the fetus too.

Indications for reperfusion in pregnancy:

Systemic thrombolysis:

Catheter-directed therapy (CDT):

Surgical pulmonary embolectomy:

IVC filter:

ECMO: VA-ECMO bridge for refractory cardiogenic shock from massive PE — feasible in pregnancy.

Special Populations — Renal and Hepatic Impairment

— Pregnancy normally increases GFR by ~50%; "normal" creatinine in pregnancy is ~0.5

— Creatinine >0.8 in pregnancy may represent renal dysfunction

— Causes: preeclampsia, acute kidney injury from hemorrhage/sepsis, underlying CKD, lupus nephritis

— Cleared renally — accumulates in CrCl <30 mL/min

— Options when CrCl <30:

— Switch to UFH (preferred — hepatic metabolism, easily monitored by aPTT)

— Or dose-reduce enoxaparin to 1 mg/kg q24h with anti-Xa monitoring (peak target 0.6–1.0)

— Renal impairment, weight extremes (<50 kg or >90 kg), recurrent VTE on therapy, mechanical heart valve, near delivery

— Peak draw 4 hours after dose

— Pregnancy-related liver pathology: HELLP syndrome, acute fatty liver of pregnancy (AFLP), intrahepatic cholestasis

— Coagulopathy from severe hepatic dysfunction may itself increase bleeding risk

— UFH preferred over LMWH if synthetic liver function severely impaired

— Avoid warfarin if INR unreliable due to liver disease

— Rare with LMWH (<1%) but possible

— Monitor platelets if UFH used >4 days

— If HIT develops in pregnancy: fondaparinux or argatroban (latter crosses placenta — limited data); danaparoid where available

Board pearl: In a pregnant patient with AKI and PE, switch from enoxaparin to UFH infusion — predictable monitoring (aPTT), rapid reversibility with protamine, no renal accumulation. Recheck platelets every 2–3 days.

Renal impairment is uncommon but consequential in pregnant patients with PE:

LMWH and renal clearance:

Anti-Xa monitoring indications in pregnancy:

Hepatic impairment:

HIT (heparin-induced thrombocytopenia):

Mechanical heart valves in pregnancy (high-risk subgroup): dose-adjusted LMWH with anti-Xa monitoring, or UFH, or warfarin in 2nd–3rd trimester — individualized.

Special Populations — Postpartum, Thrombophilia, and Recurrent VTE

— Risk peaks in first 1–2 weeks postpartum, remains elevated through 6 weeks, gradually returns to baseline by 12 weeks

— Cesarean delivery (especially emergent), postpartum hemorrhage, infection, immobility multiply risk

— Postpartum VTE prophylaxis indicated for women with risk factors (prior VTE, thrombophilia, BMI ≥40, prolonged immobility, sepsis)

— LMWH can be continued, OR transition to warfarin (bridge with LMWH until INR therapeutic ×2 days) — warfarin safe with breastfeeding

— DOACs are NOT recommended during breastfeeding — excreted in breast milk, insufficient infant safety data

— Do not test during acute PE or while on anticoagulation — many tests are unreliable

— Defer testing until ≥6 weeks after stopping anticoagulation and ideally not during pregnancy

— Test if: recurrent VTE, strong family history, unusual site thrombosis, recurrent pregnancy loss

— Panel: factor V Leiden, prothrombin G20210A, protein C/S, antithrombin, antiphospholipid antibodies (lupus anticoagulant, anticardiolipin, β2-glycoprotein I)

— Triple-positive APS or APS with prior thrombosis → lifelong anticoagulation (warfarin, NOT DOACs — increased thrombosis risk on DOACs in APS)

— APS + pregnancy: LMWH + low-dose aspirin throughout pregnancy

— Prior pregnancy-associated VTE → prophylactic or intermediate-dose LMWH throughout next pregnancy + 6 weeks postpartum

— Counsel on contraception: avoid estrogen-containing contraceptives; use progestin-only, IUD, or barrier methods

Step 3 management: Postpartum day 3 patient with new PE on cesarean recovery — start therapeutic enoxaparin, plan transition to warfarin with LMWH bridge by day 5–7, continue minimum 3 months and at least 6 weeks postpartum, counsel on progestin-only contraception, defer thrombophilia testing 6 weeks post-anticoagulation completion.

Postpartum period is the highest-risk window:

Treatment in postpartum PE:

Thrombophilia workup:

Antiphospholipid syndrome (APS):

Future pregnancy planning:

Complications and Adverse Outcomes

— Cardiac arrest and death — PE is a top cause of maternal mortality

— Right ventricular failure, cardiogenic shock from massive PE

— Chronic thromboembolic pulmonary hypertension (CTEPH) — develops in ~2–4% of PE survivors; presents months–years later with progressive dyspnea

— Post-PE syndrome — persistent dyspnea, reduced exercise tolerance, anxiety

— Recurrent VTE — risk highest in first months after stopping anticoagulation

— Major bleeding ~2% per year on therapeutic LMWH

— Postpartum hemorrhage — risk amplified if peripartum anticoagulation timing missed

— Spinal/epidural hematoma if neuraxial anesthesia performed too soon after LMWH dose

— HIT (rare with LMWH)

— Osteoporosis with long-term UFH (less with LMWH)

— Warfarin embryopathy if inadvertently used in 1st trimester

— Fetal loss from maternal shock or thrombolytic hemorrhage

— Preterm delivery — iatrogenic for maternal stabilization

— Placental abruption — from anticoagulation or shock-related ischemia

— Neonatal effects of CTPA contrast: theoretical transient hypothyroidism (check newborn TSH per local protocol)

— Fetal radiation — all standard imaging well below teratogenic threshold; lifetime cancer risk negligibly increased

— Thrombolysis: maternal intracranial/genital hemorrhage, fetal loss, preterm labor

— IVC filter: migration, IVC thrombosis, filter fracture if not retrieved

— Post-traumatic stress, depression, fear of future pregnancy — screen and refer

Key distinction: Post-PE syndrome (functional limitation, normal pulmonary pressures) vs CTEPH (elevated pulmonary pressures, RV dysfunction, treatable with pulmonary endarterectomy or riociguat). Any PE patient with persistent dyspnea >3 months after diagnosis warrants echocardiogram and possibly V/Q scan to evaluate for CTEPH.

Maternal complications:

Anticoagulation-related complications:

Fetal/neonatal complications:

Procedural complications:

Psychosocial:

When to Escalate Care — ICU, Consult, and Inpatient Triage

— Hemodynamic instability (SBP <90, vasopressor need)

— Severe hypoxemia requiring high-flow O₂, NIV, or intubation

— RV dysfunction with elevated biomarkers (submassive PE) — at minimum step-down/telemetry

— Cardiac arrest survivor

— Receiving thrombolytics or catheter-directed therapy

— Need for ECMO

— Maternal-fetal medicine (MFM) — for delivery planning, antenatal surveillance

— Hematology — anticoagulation strategy, thrombophilia, recurrence risk

— Pulmonology/cardiology — RV assessment, CTEPH surveillance

— Interventional radiology/cardiac surgery — for catheter or surgical intervention

— Anesthesiology — neuraxial timing, delivery anesthesia plan

— NICU — if preterm delivery anticipated

— PERT activation — for massive/submassive PE in many centers

— Lack of CTPA/V/Q availability after stabilization

— No PERT, no interventional capability, no Level III/IV obstetric care at presenting facility

— Hemodynamic instability + non-tertiary center → stabilize, transfer to facility with MFM, ECMO, and cardiothoracic surgery

— Stable PE remote from delivery: continue LMWH, plan to switch to UFH near term

— PE diagnosed near term: induce delivery in controlled fashion; coordinate anticoagulation hold (24 h for LMWH)

— Massive PE: deliver only if maternal stabilization requires it; otherwise stabilize first

CCS pearl: Order set for newly diagnosed PE in a 32-week pregnant patient: admit to ICU/step-down, continuous telemetry + pulse ox + EFM, enoxaparin 1 mg/kg SC q12h, MFM consult, hematology consult, anesthesia consult, mechanical compression device contralateral leg, betamethasone if <34 weeks if delivery may be needed within 7 days.

All pregnant patients with confirmed PE warrant inpatient admission — outpatient PE management protocols (e.g., HESTIA, sPESI-based discharge) are not validated in pregnancy.

ICU admission criteria:

Mandatory consults:

Transfer criteria:

Delivery planning during PE admission:

Fetal monitoring appropriate to gestational age — continuous EFM if viable (≥24 weeks) during acute illness.

Key Differentials — Other Cardiopulmonary Causes of Dyspnea/Chest Pain in Pregnancy

— Last month of pregnancy through 5 months postpartum

— LV systolic dysfunction (EF <45%) without other identifiable cause

— Echo diagnostic; treat with standard HF therapy (avoid ACE-I/ARB antepartum)

— Catastrophic intrapartum/immediate postpartum collapse

— Sudden hypoxemia, hypotension, DIC, often cardiac arrest

— Clinical diagnosis; supportive care, massive transfusion

— Preeclampsia with severe features, cardiomyopathy, iatrogenic fluid overload, tocolytic-related (terbutaline, magnesium)

— Bilateral crackles, BNP elevated, CXR with edema pattern

— Pregnancy + connective tissue disease (Marfan, Loeys-Dietz, vascular Ehlers-Danlos) ↑ risk

— Tearing chest/back pain, pulse differential, widened mediastinum

— Spontaneous coronary artery dissection (SCAD) — peripartum association, especially postpartum

— ECG changes, troponin elevation

— Supraventricular tachycardia common in pregnancy; assess for hemodynamic compromise

— Hypertension, proteinuria, pulmonary edema, seizures

— Magnesium for seizure prophylaxis

— Wheezing predominant; treat per usual stepwise care (albuterol, ICS, steroids safe)

— Acute hypotension, urticaria, bronchospasm; epinephrine IM

Key distinction: AFE vs massive PE — both cause sudden peripartum collapse with hypoxemia and shock. AFE is characterized by DIC and consumptive coagulopathy within minutes; PE is not. Both are managed supportively; thrombolysis is contraindicated in AFE (would worsen DIC bleeding).

Pregnancy alters cardiopulmonary physiology — multiple conditions mimic PE:

Peripartum cardiomyopathy:

Amniotic fluid embolism (AFE):

Air embolism — during delivery or central line placement

Acute pulmonary edema:

Aortic dissection:

Acute coronary syndrome / SCAD:

Cardiac arrhythmias:

Severe preeclampsia/eclampsia:

Acute asthma exacerbation:

Anaphylaxis:

Key Differentials — Non-Cardiopulmonary Mimics

— Fever, productive cough, focal consolidation on CXR

— Pregnant patients more susceptible to influenza, varicella, COVID-19 pneumonia (severe disease risk ↑)

— Treat per CAP guidelines with pregnancy-safe antibiotics (β-lactams, macrolides; avoid fluoroquinolones, tetracyclines)

— Small physiologic effusions common postpartum

— Larger effusions: pneumonia, malignancy, heart failure

— Spontaneous PTX rare in pregnancy but described

— Sudden pleuritic chest pain, unilateral decreased breath sounds, hyperresonance

— Reproducible chest wall tenderness; no hypoxemia or tachycardia

— Very common in pregnancy (progesterone relaxes LES); burning, postprandial, responsive to antacids

— Diagnosis of exclusion — do not anchor; rule out PE first with objective testing

— Iron-deficiency anemia common; check CBC

— Pregnancy-induced respiratory alkalosis is physiologic; subjective dyspnea common

— Tachycardia, anxiety, tremor; check TSH/free T4

— Pregnant women have ↑ pyelo risk; tachycardia and tachypnea from sepsis can mimic PE

— RUQ pain referred to chest; check LFTs, platelets, RUQ ultrasound

Board pearl: Never accept "anxiety" as the diagnosis in a pregnant or postpartum patient with dyspnea + tachycardia + hypoxemia until PE has been objectively ruled out. The single most common pre-mortem diagnosis in fatal maternal PE cases is "panic attack" or "musculoskeletal pain."

Pneumonia:

Pleural effusion (non-PE):

Pneumothorax:

Costochondritis / musculoskeletal pain:

GERD / esophagitis:

Anxiety / panic disorder:

Anemia-related dyspnea:

Hyperventilation syndrome:

Thyroid storm:

Sepsis / pyelonephritis:

Cholecystitis / HELLP / hepatic capsule distention:

Secondary Prevention, Discharge Medications, and Long-Term Plan

— Minimum 3 months total AND at least 6 weeks postpartum, whichever is longer

— If PE occurred late in pregnancy → continue until 6 weeks postpartum (often longer than 3 months total)

— Extended/indefinite anticoagulation if: APS, antithrombin deficiency, recurrent unprovoked VTE, persistent risk factors

— LMWH — safe with breastfeeding, predictable

— Warfarin — safe with breastfeeding (does not enter milk in significant amounts); requires INR monitoring 2–3

— DOACs — avoid during breastfeeding (apixaban, rivaroxaban excreted in milk; insufficient infant safety data)

— Bridge LMWH → warfarin: overlap until INR ≥2 for 2 consecutive days

— Avoid estrogen-containing contraceptives (combined OCPs, patch, ring) — VTE risk ↑

— Acceptable: progestin-only pill, levonorgestrel IUD, copper IUD, etonogestrel implant, DMPA, barrier methods, sterilization

— Discuss before discharge — pregnancy planning is part of secondary prevention

— Refer to MFM preconception

— Prophylactic or intermediate-dose LMWH throughout subsequent pregnancy + 6 weeks postpartum

— APS: LMWH + low-dose aspirin throughout pregnancy

— Defer until ≥6 weeks after stopping anticoagulation and outside pregnancy

— Test if recurrent VTE, strong family history, atypical site, recurrent pregnancy loss

— Smoking cessation, weight management, hydration, avoid prolonged immobility

— Compression stockings for post-thrombotic syndrome prevention if DVT was present

Step 3 management: Discharge bundle for postpartum PE: enoxaparin or warfarin (with patient preference and breastfeeding considered), MFM follow-up in 2 weeks, hematology follow-up in 4 weeks, progestin-only contraception or IUD, smoking cessation, echo at 3–6 months if RV strain at diagnosis to screen for CTEPH, education on bleeding precautions and recurrent PE symptoms.

Anticoagulation duration after pregnancy-associated PE:

Choice of agent after delivery:

Future contraception counseling:

Future pregnancy planning:

Thrombophilia evaluation:

Lifestyle:

Follow-Up, Monitoring, and Counseling

— 1–2 weeks post-discharge: clinic visit — assess symptoms, bleeding, anticoagulation adherence, INR if on warfarin, CBC

— 4–6 weeks: hematology — confirm therapy plan, address questions

— 3 months: decision point on continuing vs stopping anticoagulation

— 3–6 months: echocardiogram and clinical assessment for CTEPH if persistent dyspnea or initial RV dysfunction

— Postpartum visit at 6 weeks integrates contraception, mood, lactation

— Anti-Xa peak (4 h post-dose) if dosing concerns; not routinely required

— CBC at baseline, day 5–7, then periodically

— Renal function periodically

— INR target 2.0–3.0

— Check weekly until stable, then every 4 weeks

— Counsel on dietary vitamin K consistency, drug interactions

— Worsening dyspnea, chest pain, hemoptysis, syncope (recurrent PE)

— New leg swelling/pain (recurrent DVT)

— Bleeding: melena, hematuria, heavy vaginal bleeding, severe headache, easy bruising

— Pregnancy: contractions, decreased fetal movement, vaginal bleeding, leakage of fluid

— Refer if persistent functional limitation

— Gradual return to activity; counsel against prolonged immobility

— Screen for postpartum depression and post-PE anxiety/PTSD at each visit

— Refer for therapy as needed

— Influenza, COVID-19, Tdap per pregnancy/postpartum schedule

Board pearl: A postpartum woman 6 weeks after PE diagnosis with new persistent exertional dyspnea and elevated BNP needs an echocardiogram to evaluate for CTEPH — refer to pulmonary hypertension specialist if RV dysfunction or elevated PASP. Pulmonary thromboendarterectomy is potentially curative.

Outpatient follow-up cadence:

Monitoring on LMWH:

Monitoring on warfarin:

Patient counseling — symptoms warranting urgent return:

Cardiopulmonary rehabilitation:

Mental health:

Vaccinations:

Ethical, Legal, and Patient Safety Considerations

— Discuss radiation risks in absolute, accurate terms — fetal dose from CTPA or V/Q is <1 mGy, well below 50 mGy teratogenic threshold; lifetime cancer risk increase is negligible

— Document risk-benefit discussion and patient agreement

— A patient may refuse imaging — document the conversation, alternatives offered, and clinical plan

— Maternal autonomy supersedes presumed fetal interests in legal frameworks, but counseling must be thorough

— Discuss maternal hemorrhage risk (~8%), fetal loss (~6%), preterm delivery — but emphasize that withholding therapy in massive PE has ~25–50% maternal mortality

— Surrogate decision-making if patient incapacitated — partner/family per state law

— Two-physician documentation in emergent thrombolysis is good practice

— Peripartum anticoagulation timing errors are a sentinel event — handoffs between OB, anesthesia, and inpatient teams must include explicit LMWH last-dose time and next-dose plan

— Neuraxial anesthesia administered within 24 h of therapeutic LMWH → epidural hematoma, paralysis — protocolize hold times

— Discharge handoff to outpatient anticoagulation clinic with explicit follow-up date and bridging plan

— Maternal deaths from PE are reportable to state Maternal Mortality Review Committees — quality improvement, not punitive

— Black women have 3–4x higher maternal mortality in the US, including from VTE — recognize implicit bias in symptom dismissal; apply objective workup uniformly

— Pretest probability assessment, D-dimer rationale, imaging choice rationale, anticoagulation plan, contraception counseling, follow-up plan

— Confirm postpartum anticoagulant is compatible with breastfeeding (LMWH, warfarin yes; DOACs no)

Step 3 management: A laboring patient on therapeutic enoxaparin requests epidural — the safe response is delay neuraxial anesthesia until 24 hours after last therapeutic LMWH dose (or check anti-Xa); offer IV analgesia in the interim. Document discussion. This is a classic patient-safety question.

Informed consent for imaging in pregnancy:

Informed consent for thrombolysis in pregnancy:

Transition-of-care safety risks (Step 3 favorite):

Mandatory reporting and maternal mortality review:

Health equity considerations:

Documentation:

Lactation safety:

High-Yield Associations and Rapid-Fire Clinical Facts

Board pearl: The single most testable fact: In pregnant patients with suspected PE, do not withhold imaging due to radiation concerns — fetal dose is well below teratogenic threshold, and missed PE is the more dangerous outcome.

PE is a top cause of maternal mortality in high-income countries.

Risk highest in postpartum period (esp. weeks 1–6), particularly after cesarean.

Left-leg DVT predominance — gravid uterus + right iliac artery compress left iliac vein (May-Thurner physiology).

LMWH = pregnancy first-line. Warfarin teratogenic 6–12 weeks. DOACs contraindicated.

Warfarin safe in breastfeeding. DOACs not safe in breastfeeding.

D-dimer is physiologically elevated in pregnancy — use pregnancy-adapted YEARS algorithm.

CTPA preferred if abnormal CXR or alternate dx; V/Q (perfusion-only) preferred if normal CXR — both safe.

Fetal radiation from PE workup <1 mGy, well below 50 mGy threshold.

CTPA breast dose is higher than V/Q — counsel on lifetime breast cancer risk.

Thrombolysis NOT absolutely contraindicated in pregnancy — use for massive PE.

IVC filter in pregnancy → place suprarenally, prefer retrievable.

Hold LMWH 24 h before neuraxial anesthesia (12 h for prophylactic dose).

Restart anticoagulation 12–24 h postpartum depending on bleeding risk.

Duration of treatment: minimum 3 months AND at least 6 weeks postpartum.

Antiphospholipid syndrome + pregnancy: LMWH + low-dose aspirin throughout.

APS with prior thrombosis: warfarin, NOT DOACs (DOACs increase thrombosis in APS).

Avoid estrogen contraception in women with VTE history.

Thrombophilia testing deferred until ≥6 weeks after stopping anticoagulation.

CTEPH develops in ~2–4% of PE survivors — echo at 3–6 months if persistent dyspnea.

AFE vs PE: AFE has DIC, thrombolysis contraindicated.

PESI/sPESI not validated in pregnancy.

Mechanical thrombectomy increasingly preferred over systemic lysis in pregnancy.

Postpartum unilateral leg swelling + dyspnea → assume PE until proven otherwise.

Board Question Stem Patterns

— 28-year-old G2P1 at 32 weeks with sudden dyspnea, HR 118, SpO₂ 92%, left calf swelling. Next step? → Lower extremity ultrasound (if positive, treat without further imaging) or CTPA/V/Q. NOT "reassure and discharge."

— Pregnant patient with mild dyspnea, low clinical suspicion. D-dimer elevated. → Apply pregnancy-adapted YEARS; if criteria met, may avoid imaging. If pretest probability high or YEARS positive → image.

— Pregnant patient, normal CXR, suspected PE → V/Q scan preferred (lower maternal breast dose).

— Abnormal CXR or alternative dx considered → CTPA preferred.

— Newly diagnosed PE at 24 weeks gestation → Enoxaparin 1 mg/kg SC q12h (NOT warfarin, NOT apixaban).

— Patient on therapeutic enoxaparin presents in labor requesting epidural — last dose 8 h ago → Delay epidural until 24 h after last therapeutic dose, offer alternative analgesia.

— Pregnant patient with PE, SBP 78, RV strain on echo → Systemic thrombolysis with alteplase (or catheter-directed/surgical embolectomy). Pregnancy is NOT absolute contraindication.

— Breastfeeding mother with PE wants to switch from LMWH → Warfarin acceptable, DOACs not recommended.

— Woman with prior pregnancy-associated PE asks about contraception → Progestin-only or IUD; avoid estrogen.

— Prior pregnancy-associated PE plans another pregnancy → Prophylactic LMWH throughout pregnancy + 6 weeks postpartum.

— When to test? → ≥6 weeks after stopping anticoagulation, outside pregnancy.

— Pregnant PE patient with active GI hemorrhage → Retrievable IVC filter, suprarenal placement.

— Post-PE patient with exertional dyspnea → Echocardiogram for CTEPH evaluation.

Step 3 management: Recognize the "anxiety attack in postpartum patient" stem — the right answer is objective PE workup, not reassurance.

Stem 1 — Classic missed PE:

Stem 2 — D-dimer dilemma:

Stem 3 — CTPA vs V/Q choice:

Stem 4 — Anticoagulant selection:

Stem 5 — Peripartum anticoagulation timing:

Stem 6 — Massive PE in pregnancy:

Stem 7 — Postpartum agent choice:

Stem 8 — Contraception counseling:

Stem 9 — Future pregnancy:

Stem 10 — Thrombophilia testing:

Stem 11 — IVC filter:

Stem 12 — Persistent dyspnea 4 months later:

One-Line Recap

Pulmonary embolism in pregnancy demands a low-threshold, radiation-unafraid diagnostic approach (pregnancy-adapted YEARS → leg US → V/Q or CTPA), LMWH as first-line therapy throughout pregnancy with warfarin acceptable postpartum and DOACs avoided in both pregnancy and lactation, anticoagulation continued for a minimum of 3 months and at least 6 weeks postpartum, and aggressive reperfusion (including systemic or catheter-directed thrombolysis) for massive PE because maternal death is the worst outcome for both mother and fetus.

High-yield recap bullets:

Board pearl: The pregnant or postpartum patient with unexplained tachycardia, dyspnea, or hypoxemia has PE until objectively proven otherwise — bias toward workup, not reassurance, because PE remains a leading cause of preventable maternal death.

Diagnose aggressively: Pregnancy-adapted YEARS algorithm + lower extremity ultrasound first; V/Q if normal CXR, CTPA if abnormal CXR — fetal dose <1 mGy is far below the 50 mGy teratogenic threshold; never withhold imaging from a symptomatic pregnant patient.

Treat with the right drug: LMWH (enoxaparin 1 mg/kg SC q12h) is the pregnancy standard — does not cross placenta. Warfarin is teratogenic in pregnancy but safe in breastfeeding. DOACs are contraindicated in both pregnancy and lactation. Switch to UFH near delivery for reversibility; hold LMWH 24 h before neuraxial anesthesia.

Stratify and escalate: Submassive PE (RV strain, elevated troponin/BNP) → monitored bed, MFM/hematology/anesthesia consults, PERT activation. Massive PE (shock) → systemic thrombolysis is NOT absolutely contraindicated in pregnancy — alteplase or mechanical thrombectomy is appropriate; maternal mortality without reperfusion is 25–50%.

Plan the long game: Minimum 3 months anticoagulation AND at least 6 weeks postpartum; offer progestin-only contraception (avoid estrogen); plan prophylactic LMWH in future pregnancies; defer thrombophilia testing until 6 weeks off therapy; screen for CTEPH at 3–6 months if persistent dyspnea; address maternal mental health and post-PE syndrome.